Emanuelle Sedita

MBA, Finance, May 2027 2025 – 2027

Honors

Henry Kravis Scholar

Leadership

IB Club AVP of Finance

Memberships

HCIA, Football Club, Ski Club, Gourmet Club, Poker Club, The Consortium

BBA, Finance & Economics, May 2018 2014 – 2018

Honors

cum laude, Beta Alpha Psi

Leadership

Hall Street Fund VP

Memberships

SMIF, ALPFA

Healthcare IB – Summer AssociateSummer 2026

• Supported execution of five live buy- and sell-side mandates across MedTech, Biopharma, and HC Services totaling $60B+ in expected transaction value through financial modeling, due diligence and various client presentation materials
• Drafted business and MD&A sections of a Form 10 registration statement for a ~$20B planned MedTech separation, coordinating inputs across company management, legal counsel, and senior deal team
• Independently authored a 24-page strategic alternatives pitch on Solventum recommending a tax-free spin of its HIS segment vs. a ~$7.1B sale; built DCF, LBO, comps, precedents, and SOTP models quantifying strategic decision making

MedTech GSI – Manager2024 – 2025

• Led cross-functional buy-side commercial diligence across wound care, focal energy oncology, robotics, and Open/MIS external innovation targets for ICs including CEO, CFO, BD, and Commercial leadership within a ~$32B portfolio
• Built bottom-up US/OUS revenue models for $1B+ acquisitions/R&D projects; delivered base/upside/downside models with tornado sensitivities to support NBIO/BO valuations, influence deal terms/structure, and overall GTM integration strategy
• Led C-suite/banker diligence calls and directed external consultants for KOL research to validate competitive conversions, surgeon specialty behavior, and product market landscapes tightening peak and competitive market-share capture in revenue models
• Triangulated IQVIA claims, competitive diligence, and KOL research to size $2B+ TAM/SAM into SOM and peak-share ramps
• Produced executive fact packs that bridged revenue assumptions, projections, and market insights for CEO/CFO/BD IC
• Aligned Regulatory, Finance, BD, and Commercial leadership on product landscape, GTM strategy, and launch timing

MedTech Surgery SCG – Sr. Financial Analyst2022 – 2024

• Developed financial analytics to support leadership’s major pricing strategy shift in the MedTech Surgery portfolio and sales/account management personnel restructuring contributing ~$50M in top-line growth for FY’25 enabling 250+ new hires
• Owned individual customer P&L’s and created GPO pricing-tier models across ~$5.6B sales; drove portfolio-level price actions and led weekly exec reviews to align leadership in strategic pricing/deals to accelerate decisions
• Optimized volume/mix/price financial strategy and supported negotiation of contracts/bundles driving ~$200M in revenue

MedTech Ortho Commercial Excellence – Sr. Financial Analyst2021 – 2022

• Managed ~$1.3B in commercial S&M budgets supporting ~$5.2B in revenue; developed in-depth knowledge of tiered and product-specific compensation plans for ~2.7K headcount through cross-functional partnership with senior leadership
• Led financial analysis for a sales force restructuring enabling ~$25M investment into hiring 100+ new sales resources
• Partnered with senior finance management on developing and presenting quarterly results to the US MedTech CFO

Corporate Functions – Financial Analyst (FLDP)2019 – 2020

• Managed $60M in talent development and recruitment budgets using revamped quarterly reporting packages and Tableau dashboards; identified and addressed budget risks and opportunities across headcount, travel, and project spend
• Demonstrated strategic financial leadership to solve $2M gap, prioritize key projects, and restructure talent teams

MedTech SC FP&A – Assoc. Financial Analyst (FLDP)2018 – 2019

• Consolidated decks, developed reporting, and provided commentary for ~$6B in worldwide P&L statements, cost improvement projects, and SC finance metrics delivered directly to the US MedTech SC CFO/VPs
• Lead analyst directing budgets for a major $300M SC initiative outsourcing product production to Jabil